SUZHOU, China, and ROCKVILLE, MD, Oct 12, 2023—Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) has approved a global pivotal registrational Phase III study designed to Read More ›

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its 2023 interim results. During the reporting period, Ascentage Pharma remained steadfastly committed to its strategy of original innovation and global innovation, having achieved multiple milestones in key aspects of its business Read More ›

Ascentage Pharma (6855.HK) announced today that lisaftoclax (APG-2575), a novel Bcl-2 inhibitor and one of the company’s core assets, has been cleared by the US Food and Drug Administration (FDA) to enter a global registrational Phase III study for treatment of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who were BTKi previously treated . Read More ›

Ascentage Pharma (6855.HK) announced today that it is going to release results from two clinical studies at the 2023 European Society of Medical Oncology (ESMO) Congress. These presentations include a Mini Oral featuring the latest data from a study of pelcitoclax (APG-1252), a Bcl-2/BcL-xL dual-targeted inhibitor, combined with osimertinib in patients with EGFR-mutant non-small cell Read More ›

Ascentage Pharma (6855.HK) announced today that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has approved a registrational pivotal Phase III study of olverembatinib, Ascentage Pharma’s lead drug candidate, in combination with chemotherapy (investigational arm) comparing imatinib in combination with chemotherapy (control arm) for treatment of patients with naïve Read More ›

Ascentage Pharma (6855.HK) announced today that it has released preliminary results from a Phase Ib/II study of the Bcl-2 inhibitor, lisaftoclax (APG-2575), as a monotherapy or combined with ibrutinib or rituximab in patients with Waldenström macroglobulinemia (WM), in a Poster Presentation at the 59th American Society of Clinical Oncology (ASCO) Annual Meeting that marked the Read More ›

Ascentage Pharma (6855.HK)  announced today that for the second consecutive year, it has released updated data of APG-2449, a novel FAK/ALK/ROS1 tyrosine kinase inhibitor (TKI) developed by Ascentage Pharma, in patients with non-small cell lung cancer (NSCLC), in a Poster Discussion session at the 59th American Society of Clinical Oncology (ASCO) Annual Meeting. Showcasing progress Read More ›

Ascentage Pharma (6855.HK) announced today that it has released updated results from a Phase II study of MDM2-P53 inhibitor, alrizomadlin (APG-115), in combination with pembrolizumab in patients with unresectable or metastatic cutaneous melanoma that had failed immuno-oncologic (IO) drugs in a Poster Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting. This data Read More ›

Live from ASCO 2023 | Updated Data of Olverembatinib in SDH-Deficient GIST including a CBR of 93.8% Signals a Potential Clinical Breakthrough Ascentage Pharma (6855.HK) announced today that it has released updated clinical results of olverembatinib (HQP1351), a third-generation tyrosine kinase inhibitor (TKI), in patients with TKI-resistant succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumor (GIST), in Read More ›

SUZHOU, China, and ROCKVILLE, MD, June 5, 2023—Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that its Clinical Advisory Board member Prof Hagop M. Kantarjian has received the David A. Karnofsky Memorial Award for his lifelong contributions to leukemia clinical Read More ›